


## N-Bromoacetyl-β-alanine

Cat. No.:	HY-141379
CAS No.:	89520-11-6
Molecular Formula:	C <sub>5</sub> H <sub>8</sub> BrNO <sub>2</sub>
Molecular Weight:	210.03
Target:	PROTAC Linkers; ADC Linker
Pathway:	PROTAC; Antibody-drug Conjugate/ADC Related
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



### SOLVENT & SOLUBILITY

In Vitro	DMSO : 62.5 mg/mL (297.58 mM; Need ultrasonic)					
	Preparing Stock Solutions	Solvent Concentration	Mass	1 mg	5 mg	10 mg
		1 mM		4.7612 mL	23.8061 mL	47.6122 mL
		5 mM		0.9522 mL	4.7612 mL	9.5224 mL
		10 mM		0.4761 mL	2.3806 mL	4.7612 mL
Please refer to the solubility information to select the appropriate solvent.						
In Vivo	<ol style="list-style-type: none"> <li>Add each solvent one by one: 10% DMSO &gt;&gt; 40% PEG300 &gt;&gt; 5% Tween-80 &gt;&gt; 45% saline Solubility: ≥ 2.08 mg/mL (9.90 mM); Clear solution</li> <li>Add each solvent one by one: 10% DMSO &gt;&gt; 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.08 mg/mL (9.90 mM); Clear solution</li> <li>Add each solvent one by one: 10% DMSO &gt;&gt; 90% corn oil Solubility: ≥ 2.08 mg/mL (9.90 mM); Clear solution</li> </ol>					

### BIOLOGICAL ACTIVITY

Description	N-Bromoacetyl-β-alanine is an alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs <sup>[1]</sup> . N-Bromoacetyl-β-alanine is also a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs) <sup>[2]</sup> .	
IC <sub>50</sub> & Target	Alkyl-Chain	Cleavable
In Vitro	PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins <sup>[1]</sup> . ADCs are comprised of an antibody to which is attached an ADC cytotoxin through an ADC linker <sup>[2]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	

---

## REFERENCES

- [1]. An S, et al. Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs. *EBioMedicine*. 2018 Oct;36:553-562.
- [2]. Beck A, et al. Strategies and challenges for the next generation of antibody-drug conjugates. *Nat Rev Drug Discov*. 2017 May;16(5):315-337.
- 

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA